Telix Pharmaceuticals is planning to release the first targeted PET imaging agent for kidney cancer in 2024. The Australian company has submitted a license application to the FDA for its investigational agent TLX250-CDx, and has been granted a rolling review process for priority consideration. The submission comes after the successful completion of Phase 3 of the ZIRCON study, which demonstrated the superior sensitivity and specificity of the agent in diagnosing clear cell renal cell carcinoma, the most aggressive form of kidney cancer. If approved, TLX250-CDx will be the first agent to target carbonic anhydrase IX, a key molecular target in kidney cancer.
Tue, 19 Dec 2023 03:53:26 GMT | Radiology Business